Drug Approval | October 04, 2024
Shilpa Pharma Lifesciences receives CEP from EDQM for API, Desmopressin
This is used to treat central diabetes insipidus and bedwetting
This is used to treat central diabetes insipidus and bedwetting
Cetirizine is used for relief of symptoms of hay fever and other allergic conditions
Alcaftadine Ophthalmic Solution, 0.25% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair, and dander
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
Lamotrigine extended-release tablets are indicated for adjunctive therapy for primary generalized tonic-clonic seizures and partial-onset seizures
Enzalutamide Tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
This facility underwent an inspection from 15th to 19th July 2024 and has been classified as Voluntary Action Indicated
The product is expected to be launched in Q3FY25
The inspection conducted by EDQM at its Visakhapatnam facility
Subscribe To Our Newsletter & Stay Updated
